Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers December 18, 2014
Pharmacy Choice - Pharmaceutical News - Advaxis Live Listeria Prostate Cancer Vaccine Heads for Clinic - December 18, 2014

Pharmacy News Article

 4/30/10 - Advaxis Live Listeria Prostate Cancer Vaccine Heads for Clinic

NORTH BRUNSWICK, N.J.(BUSINESS WIRE) Advaxis, Inc., (OTCBB: ADXS). Advaxis, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is advancing the clinical development of its lead prostate cancer immunotherapeutic toward clinical trials.

The company is collaborating with Dr. Chandan Guha at the Albert Einstein College of Medicine and Montefiore Medical Center to develop ADXS31-142 in human trials. Following the completion of manufacturing trials, the company intends to conduct a Phase 1 study with Dr. Guha.

Regarding Advaxis prostate initiative, Dr. John Rothman, Executive VP of Science and Operations said, Prostate cancer is an excellent target for immunotherapy. We believe our approach compares favorably with the recently approved Provenge treatment. Advaxis vaccine is simple and less expensive, as it is comprised of three (3) vaccinations, which attack all prostate cancer without the need to be patient specific.?

Advaxis prostate cancer vaccine generates a strong immunologic response that attacks and kills cells that secrete prostate specific antigen (PSA), a commonly used clinical indicator of prostate cancer. The company has published preclinical work demonstrating the ability of ADXS31-142, its live Listeria vaccine directed against PSA (Cancer Immunology Immunotherapy. 2008, 57:13011313; Clinical & Vaccine Immunology, 2009, 16(1):96103).

"The approval of Dendreon Corporation's (NASDAQ: DNDN) Provenge by the Food and Drug Administration (FDA) is an exciting development in the study of cancer immunotherapy. Our collaboration with Dr. Guha, coupled with our recent success in raising funds and some very promising new preclinical research has led us to commit to moving forward immediately on a prostate program with our proprietary live Listeria technology platform,"commented Advaxis Chairman/CEO Thomas A. Moore. "If human results approach our animal results, we may be able to offer an immunotherapy that is less expensive, more effective and suitable for use prior to the induction of chemical castration of prostate cancer patients.?

About Dr. Chandan Guha

Dr. Guha is Professor of Radiation Oncology and Professor of Pathology at the Albert Einstein College of Medicine and Vice-Chairman of Radio-oncology at the Montefiore Medical Center. He is a member of the National Cancer Institute's Radio-Therapy Oncology Group (RTOG). Dr. Guha has received numerous awards and grants in support of his work.

About Advaxis, Inc.

Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) immunotherapeutics that deliver engineered tumor antigens, which stimulate multiple, simultaneous, immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research UK. The Company's technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis scientific advisory board. Please visit the Company's portals: | facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.

Advaxis, Incorporated
Conrad F. Mir, 732-545-1590
Executive Director
732-545-1084 (FAX)
Diana Moore, 732-545-1590
732-545-1084 (FAX)

Source: Advaxis, Inc.

Copyright Business Wire 2010

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Dec 18: Anticoagulants: The Rapidly Changing Landscape
Last Chance
Dec 19: Is the Patient Comfortable in Their Skin?: Recommendations for Eczema & Dry Skin
Dec 21: Medical Marijuana: Examining the Science, Not the Politics
Dec 22: Update on the Treatment of Schizophrenia
Dec 23: Motivation: The Key to Improving Patient Outcomes
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement